Speech-Language Pathologists in Castle Rock, WA Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Mrs. Sally Bern Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 700 Huntington Ave S, Castle Rock, WA 98611 Phone: 360-501-2910 |
Mrs. Summer Noel Catlin, M.S.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Huntington Ave S, Castle Rock, WA 98611 Phone: 360-501-2904 |
News Archive
Proposal to impose tax on insurers for individual health insurance plans is unfair and unnecessary: Teamsters
Teamsters General President Jim Hoffa today said the proposal to impose a 35 percent tax on insurers for individual health insurance plans worth more than $8,000 is unfair and unnecessary.
Sorrento Therapeutics merge with subsidiary of Quikbyte Software
Sorrento Therapeutics, Inc. ("STI"), a privately-held and development-stage biopharmaceutical company with a proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, has merged with a wholly-owned subsidiary of QuikByte Software, Inc. (OTC Bulletin Board: QBSW), a publicly-traded company with no active operations.
Social injustice is killing people on a grand scale reports WHO's Commission
A child born in a Glasgow, Scotland suburb can expect a life 28 years shorter than another living only 13 kilometres away. A girl in Lesotho is likely to live 42 years less than another in Japan. In Sweden, the risk of a woman dying during pregnancy and childbirth is 1 in 17 400; in Afghanistan, the odds are 1 in 8. Biology does not explain any of this. Instead, the differences between - and within - countries result from the social environment where people are born, live, grow, work and age.
Exactech's new Optetrak Logic knee implant effective for painful arthritis
Kevin Hindle, a 47-year-old manufacturing engineer at Exactech, Inc., a global orthopaedic device company, regained his active lifestyle with an innovative new knee implant that he helped develop.
PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).
› Verified 5 days ago